Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Article

January 9, 2020

Findings Show No Statistically Significant Link Between Talcum Powder And Ovarian Cancer

Author(s):

Conor Killmurray

In a new study, researchers set out to prove whether or not there was a statistically significant risk of ovarian cancer from the use of talc-based powder.

here is not a statistically significant association between the use of powder in the genital area and risk for ovarian cancer, according to a new study published in JAMA Network.

In the past, many high-profile court cases have seen patients with ovarian cancer go back and forth with major manufactures of talc powder, like Johnson & Johnson, over whether or not their Baby Powder product was responsible for ovarian cancer risk that led to the cancer itself in some patients. This fear of talcum powder causing ovarian cancer comes from the fact that it is made from the mineral talc which in its natural form contains asbestos that is known to cause cancer along the lungs when inhaled. In 1976 the Cosmetic, Toiletry, and Fragrances Association (CTFA) issued guidelines that all talc used in cosmetic products should be free of detectable amounts of asbestos, and talc use is no longer considered a carcinogenic.

According to the American Cancer Society, it is generally accepted that talc with asbestos in it can cause lung cancer when inhaled, but the information on asbestos-free talc is not as clear or accepted. Other study results have been mixed, or determined to be biased, in their answer of whether or not there is an association between talc and risk for ovarian cancer.

“Case-control studies have reported positive associations between use of powder in the genital area and ovarian cancer,” the researchers for this four-cohort study wrote. “However, these findings may be affected by recall bias, and a recent surge in talc-related lawsuits and media coverage has increased this possibility. Thus, it is crucial to evaluate the talc—ovarian cancer association using prospective data.”

Pooling data from the Nurse’s Health Study, Nurses’ Health Study II, Sister Study, and Women’s Health Initiative Observational Study, researchers studied a total sample group of 252,745 women—38% of the participants self-reported their use of powder in the genital area, 10% reported long-term use and 22% reported frequent use of talc-based powder. From this sample group, 2,168 women developed ovarian cancer over the years of the study under investigation; however, of note, women with pre-existing ovarian cancer were excluded from the study to avoid recall basis.

When looking at the overall sample group, the estimated risk of ovarian cancer for women 70 years old unexposed to talcum powder was 1.16% compared to those exposed. The risk of ovarian cancer for women considered long-term users of talc powder compared to those that never used talc powder was .01% and frequent users' risk of ovarian cancer compared to the same control group was only .10%.

“There was no statistically significant association between self-reported use of powder in the genital area and risk of ovarian cancer,” researchers concluded. “There were no clear dose-response trends for duration and frequency of powder use in the genital area in relation to ovarian cancer risk.”

Researchers were willing to note that the study might have been underpowered, meaning it was still not large enough, to identify if there is a small increase in risk between the use of talc-based powder and ovarian cancer.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Image of woman.
Dr. Alex Francoeur interviewing against a gray CURE background
Kristie L. Kahl and Dr. Debra Richardson
Related Content
Advertisement
Image of ovary.
May 8th 2025

The OVATION 3 Study Initiates First Trial Site for Ovarian Cancer

Ryan Scott
The first trial site has been initiated in the pivotal phase 3 OVATION 3 study which will investigate IMNN-001 for newly diagnosed advanced ovarian cancer.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of ovary.
May 2nd 2025

First Patient Dosed With Azenosertib in Cyclin E1+ Ovarian Cancer

Ryan Scott
The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 DENALI clinical trial.
Shannon Miller smiling at a podium while delivering the keynote address at the 2023 Extraordinary Healer event | Image credit: © ATA-GIRL PHOTOGRAPHY
May 4th 2023

Olympian Shares Her Cancer Experience: ‘Give Yourself Grace’

Brielle Benyon
Olympic gymnast, Shannon Miller, sat down with CURE® to discuss her experience with a rare type of ovarian cancer, and how her competitive mindset helped her through.
Rendering of an ovary with a tumor
April 7th 2025

BELLA Clinical Trial Initiated in Platinum-Resistant Ovarian Cancer

Alex Biese
The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ovarian cancer has been launched.
Illustration of ovaries.
April 3rd 2025

Development of Nemvaleukin for Platinum-Resistant Ovarian Cancer Halted

Alex Biese
A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on to final analysis.
Related Content
Advertisement
Image of ovary.
May 8th 2025

The OVATION 3 Study Initiates First Trial Site for Ovarian Cancer

Ryan Scott
The first trial site has been initiated in the pivotal phase 3 OVATION 3 study which will investigate IMNN-001 for newly diagnosed advanced ovarian cancer.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of ovary.
May 2nd 2025

First Patient Dosed With Azenosertib in Cyclin E1+ Ovarian Cancer

Ryan Scott
The first patient with Cyclin E1+ platinum-resistant ovarian cancer has been dosed with azenosertib in part 2a of the phase 2 DENALI clinical trial.
Shannon Miller smiling at a podium while delivering the keynote address at the 2023 Extraordinary Healer event | Image credit: © ATA-GIRL PHOTOGRAPHY
May 4th 2023

Olympian Shares Her Cancer Experience: ‘Give Yourself Grace’

Brielle Benyon
Olympic gymnast, Shannon Miller, sat down with CURE® to discuss her experience with a rare type of ovarian cancer, and how her competitive mindset helped her through.
Rendering of an ovary with a tumor
April 7th 2025

BELLA Clinical Trial Initiated in Platinum-Resistant Ovarian Cancer

Alex Biese
The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ovarian cancer has been launched.
Illustration of ovaries.
April 3rd 2025

Development of Nemvaleukin for Platinum-Resistant Ovarian Cancer Halted

Alex Biese
A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on to final analysis.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.